SCHEMBL11997505

CO[C@H]1OC(COS(=O)(=O)O)[C@@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3OC(COS(=O)(=O)O)[C@@H](O[C@H]4C[C@H](O)[C@H](O[C@@H]5OC(CO)[C@@H](O[C@H]6C[C@H](O)[C@H](O[C@@H]7OC(COS(=O)(=O)O)[C@@H](O[C@H]8C[C@H](O)[C@H](O)CO8)[C@H](O)C7C)CO6)[C@H](O)C5C)CO4)[C@H](O)C3C)CO2)[C@H](O)C1C

nearest known ligand 0.38

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	FGF1	P05230	3/20	0.38

▸	F10	P00742	1/20	0.32

▸	HPSE	Q9Y251	2/20	0.31

▸	STAT3	P40763	2/20	0.31

▸	AMY1A	P0DUB6	1/20	0.31

▸	SERPINC1	P01008	1/20	0.30

▸	BLM	P54132	1/20	0.30

▸	RECQL	P46063	1/20	0.30

▸	TDP1	Q9NUW8	1/20	0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL11997504	1.00	FGF1 (0.38)	FGF1F10HPSESTAT3AMY1A
SCHEMBL11997478	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11997483	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11921934	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11997469	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11997485	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11921923	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11921938	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11921942	0.89	BLM (0.38)	FGF1BLMRECQLTDP1
SCHEMBL11997482	0.89	BLM (0.38)	FGF1BLMRECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9012413-B2	FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof	SANOFI (FR)	2015-04-21	—	—	US	disclosed
US-20120214754-A1	FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	SANOFI (FR)	2012-08-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120214754-A1	FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	FGFR1, FGF2, FGFR3	FGF1 5/4885F10 597/4885HPSE 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.